Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05733611
Title RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Replimune Inc.
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST